Find Clinical Trial

Home » Find Clinical Trials » Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day given orally with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day given orally with blinded potential adjustment to 20mg/day).

Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day given orally with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day given orally with blinded potential adjustment to 20mg/day).

← Back

Study Phase	Phase 3

Therapeutic Area	Neuropsychiatric Diseases

Indication	Major Depressive Disorder

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	AGOMELATINE, S020098

Active Substance Code	S020098

Protocol Code	CL3-20098-083

EudraCT Code	2010-023576-10

ISRCTN Code	ISRCTN28327843

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.